Biovica

Pre-clinical

Uppsala, SwedenFounded 2009biovica.com

Founded in 2009, Biovica is dedicated to transforming cancer care management through innovative biomarker-based tests. Its core technology, the DiviTum® TKa test, has been validated in over 4,500 patients across 28 publications and is supported by 32 pharmaceutical projects. With regulatory clearances in the US and EU, and a CLIA-certified lab in San Diego, Biovica is positioned to enable more confident treatment decisions by providing early and sensitive monitoring of therapy efficacy.

Founded

2009

Focus

Diagnostics

AI Company Overview

Technology Platform

Blood-based biomarker assay measuring thymidine kinase activity (TKa), an enzyme indicative of cell proliferation, for monitoring therapy response and disease progression in cancer.

Funding History

Total raised: $23M

PIPE$8MAvanza BankJun 15, 2021

IPO$15MCarnegie Investment BankOct 15, 2020

Opportunities

Significant growth opportunities exist in expanding the clinical utility of DiviTum TKa within breast cancer (e.g., neoadjuvant settings, other drug classes) and into new solid tumor indications like prostate or lung cancer.

The 32 active pharma projects represent a near-term revenue and validation pathway through companion diagnostic and clinical trial biomarker partnerships.

Risk Factors

Key risks include slower-than-expected commercial adoption by oncologists, challenges in securing adequate reimbursement from payers, competition from other liquid biopsy technologies (especially ctDNA), and ongoing financial reliance on equity financing (rights issues) to fund operations before achieving profitability.

Competitive Landscape

Biovica competes with traditional imaging (CT/PET), other liquid biopsy tests (e.g., Guardant Health's ctDNA assays), and standard serum protein biomarkers. Its differentiation lies in providing a simple, cost-effective, proliferation-specific blood test with strong clinical validation in breast cancer for serial monitoring, offering earlier response signals than imaging.